Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses lessons learned and best practices that have emerged as a result of different approaches to value assessment.
Devin Incerti, PhD, lead economist, Innovation and Value Initiative, discusses lessons learned and best practices that have emerged as a result of different approaches to value assessment.
Transcript
Looking at different approaches to value assessment, what lessons learned and best practices have emerged?
One of the most common ways to do value assessment is what I would call a conventional cost-effectiveness analysis. This is used particularly in Europe, but really around the world, and they’ve been doing it for the last 40 years or so. What that means is that the methods are very well-established, we have good ways to do it, and it lets us help guide decision making. We can use it to set prices, we can use it to make coverage decisions, we can assess uncertainty. If you’re a decision maker, you might not want to just make a decision; you might want to know the uncertainty you have with that decision, and luckily those methods let us do that.
One other thing: the conventional cost-effectiveness lets us think about opportunity costs, which is, in my mind, a very important concept. If you’re introducing a new technology, it’s not free. There’s something else you could have done instead. You might have to displace a particular investment that’s already there. You might have to spend less on healthcare, or more on healthcare and less on other goods and services in the economy. And cost-effectiveness lets us do all of those things.
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More